Navigation Links
Derma Sciences Announces First Commercial Sales of BIOGUARD(TM) Barrier Dressings
Date:6/23/2009

PRINCETON, N.J., June 23 /PRNewswire-FirstCall/ -- Derma Sciences, Inc. (OTC Bulletin Board: DSCI), a provider of advanced wound care products, announced today that it has begun shipping BIOGUARD(TM) Barrier Dressings to customers. Separately, the company announced that it has been awarded reimbursement codes for the dressings, allowing the products to be reimbursable by Medicare. BIOGUARD will offer surgeons, wound care clinicians, infection control experts and primary care doctors a new weapon against the transmission of such virulent bacteria as Methicillin-resistant Staphylococcus aureus (MRSA).

Speaking about the commencement of product sales, Derma Sciences' CEO Ed Quilty stated, "We are very excited about the sales potential for this product, and are highly encouraged by both the initial orders and positive feedback we have received from customers. We expect BIOGUARD to quickly become one of our most successful new brands in the $14 Billion global wound care market." Quilty continued, "With the ability to kill 99.999% of MRSA and other virulent pathogens, we believe these gauze-based dressings will become an important everyday asset to healthcare providers as they look for more effective and efficient ways to help prevent infections as well as cross-contaminations."

BIOGUARD Barrier Dressings were in vitro tested with the AATCC 100 antimicrobial assay, and the following results were achieved against a broad spectrum of species:

                                                            Average
    Test                                                    Log
    Species                                                 Reduction

    Methicillin-resistant staphylococcus aureus: MRSA    6.06 (>99.9999%)
    Staphylococcus aureus                               7.10 (>99.99999%)
   
'/>"/>
SOURCE Derma Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. American Academy of Dermatology Association Commends Texas for Enacting the Most Restrictive Indoor Tanning Law in the Country
2. Florida Dermatologists Announce Distinguished Service Award Winner
3. Echo Therapeutics and Handok Pharmaceuticals Sign South Korea License for Needle-free Symphony(TM) Transdermal Continuous Glucose Monitoring System
4. New State of the Art Dermatology Center in Plano TX
5. Video: BeautyScoop(R) Is a Trip to Your Nutritionist and Dermatologist in One Single Packet. Lauren Slayton, NYC Nutritionist & Owner of FoodTrainers
6. Florida Dermatologists Name Albert J. Nemeth, MD, Society President
7. Florida Dermatologists Announce Practitioner of the Year
8. American Academy of Dermatology Issues New Guidelines For the Management of Psoriasis With Systemic Medications
9. Orlando Dermatology Aesthetic & Clinical (ODAC) Conference Announces Its 2010 Event
10. American Academy of Dermatology Recognizes Merz Pharmaceuticals
11. Online System Could Cut Referrals to Dermatologists
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... , ... July 31, 2015 , ... ZH Healthcare announces ... 2015. , What is HITaaS? Health IT as a Service (HITaaS) is a Healthcare ... as a service (SaaS). , HITaaS manages all aspects of infrastructure, ...
(Date:7/31/2015)... ... July 31, 2015 , ... The Women's Excellence ... for Natural Birth . The Karmanos Center for Natural Birth provides a ... With nurses and caregivers that are trained in holistic birth approaches, patients can ...
(Date:7/31/2015)... , ... July 31, 2015 , ... Physical therapy for knee osteoarthritis ... patient's quality of life. It keeps the patient from doing what they want or need ... have a hard time using the stairs. The patient's exercise regime may be limited by ...
(Date:7/31/2015)... ... 2015 , ... EB Medicine, leading publisher of clinical journals, ... to announce that it has partnered with AgileMD to release Pediatric Emergency ... Android smartphones and tablets. , “The April 2015 launch of our flagship ...
(Date:7/31/2015)... ... July 31, 2015 , ... New Energy Works Timberframers invites the public ... Oregon August 15th, 2015 from 9am – 12pm. Timber frame raisings are ... the entire community as the culmination of months of effort, planning, fundraising, and dreaming ...
Breaking Medicine News(10 mins):Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 2Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 3Health News:ZH Healthcare Unveils Health IT as a Service (HITaaS) at OSEHRA 2015 4Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 2Health News:NYDNRehab Is the First Clinic in NYC to Provide APOS Therapy Based on Results of Complete Gait Analysis 3Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 2Health News:EB Medicine Launches Mobile Application for Pediatric Emergency Medicine 3Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 2Health News:Timber Frame Raising: Granary District Stage Amphitheater Timber Frame Hand-Raising by New Energy Works Timberframers 3
... Best Care Senior,Services has expanded into the Littleton/Denver, ... Service, and Personal,Response Company, is proud to announce ... Care Senior Services for outstanding care. For over ... of our work -- a,sincere concern for the ...
... Blood and Plasma Donor Centers, LENEXA, Kan., ... MEDW ), a provider of ClosedLoop(TM) clinical,systems for ... has,completed the acquisition of substantially all of the ... provider of software products and,services that enable blood ...
... Industry Sales Increase as Consumers Put Their Trust in Natural, Effective ... ... Oct. 31 There has been a profound shift in,the thinking ... become increasingly proactive in seeking more natural means to fight,sickness. As ...
... machinery in a cell to serve their own needs. According ... to gain access to that machinery. , A common target ... or pRb, which serves to block cell division when potentially ... of the retina, this tumor suppressor protein has since been ...
... if drug would have same benefit for Caucasians , , ... cancer with an experimental chemotherapy drug after surgery improved ... , The results of the trial won,t mean much ... S-1, is classified as "investigational" in the United States. ...
... The Medicare bidding,program for durable medical equipment will ... unless Congress modifies,the program. This is the key ... today by the American Association for Homecare.,The Association ... care, choice of provider, and access to the ...
Cached Medicine News:Health News:Announcing Always Best Care Senior Services Expansion Into the Littleton/Denver, Colorado Area 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 2Health News:Mediware Completes Acquisition of Integrated Marketing Solutions 3Health News:Hyland's Inc. Reports More Consumers Turn to Homeopathic Medicines to Fight Illness at Home 2Health News:How one virus uses mimicry to replicate successfully 2Health News:Chemo Drug Improves Stomach Cancer Survival for Japanese Patients 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 2Health News:Medicare Bidding for Durable Medical Equipment Will Harm Small Businesses and Seniors' Access to Care, American Association for Homecare Testifies 3
(Date:7/31/2015)...  Semler Scientific, Inc. (Nasdaq: SMLR ), a ... insurers and physician groups, today reported financial results for ... "In the second quarter of 2015, Semler reported ... 54%, quarter over quarter revenue growth of 8%, and ... FloChec® units of 18%," said Doug Murphy-Chutorian, M.D., chief ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 ... Eisai Co., Ltd. (Headquarters: Tokyo , ... Halozyme Therapeutics, Inc. (Headquarters: San Diego, California ... , "NASDAQ: HALO") have signed a clinical collaboration agreement ... , "eribulin") in combination with Halozyme,s investigational drug PEGPH20 ...
(Date:7/31/2015)... MONROVIA, Calif. , July 31, 2015  Xencor, ... developing engineered monoclonal antibodies for the treatment of autoimmune ... the appointment of Yujiro S. Hata to ... of experience in business and corporate development is a ... , Ph.D., president and chief executive officer of Xencor. ...
Breaking Medicine Technology:Semler Reports Second Quarter 2015 Financial Results 2Semler Reports Second Quarter 2015 Financial Results 3Semler Reports Second Quarter 2015 Financial Results 4Semler Reports Second Quarter 2015 Financial Results 5Semler Reports Second Quarter 2015 Financial Results 6Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Xencor Appoints Yujiro S. Hata to Board of Directors 2Xencor Appoints Yujiro S. Hata to Board of Directors 3
... , SANTA ... nonpartisan 501(c)3 nonprofit public charity dedicated to promoting critical thinking, ... core question "Should any vaccines be required for children?" , ... certain vaccinations for children entering public schools. Depending on the ...
... ... Walking for People With All Types of Multiple Sclerosis , ... Food and Drug Administration has approved the marketing of Ampyra™ (dalfampridine, ... to improve walking speed in people with any type of multiple ...
Cached Medicine Technology:Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 2Should Any Vaccines Be Required for Children? Pros and Cons and Current Research at New ProCon.org Website 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 2Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 3Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 4Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 5Ampyra is First Symptom Management Drug Developed Specifically to Treat MS, the First Oral MS Therapy Approved for MS, and the First New FDA Approved Therapy to Come Through the MS Pipeline Since 2004 6
... System is the next generation ... the symptoms of BPH. This ... the prostate while dilating the ... well tolerated by patients and ...
... proud to announce the release of the OES ... optics with our most commonly used cystoscopy sheaths ... level. Now you can have one instrument that ... the OES Pro cystoscopes offer a superior channel ...
... Defibrillator is a simple "1, 2, ... is compact with a streamline design ... only 13.5 lbs. It rapidly charges ... has full summary pre- & post-event ...
Incontinence Pessaries...
Medicine Products: